While significant progress has been made with immunotherapy for blood cancers, its effectiveness in treating solid tumors remains limited. A key factor contributing to this low success rate is the ...
Chimeric antigen receptor (CAR)-T cell immunotherapy has considerably changed the landscape of treatment options for blood cancers. CAR-T therapy aims to redirect a patient’s T cells to recognize and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results